SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2051083

Cover Image

PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2051083

GLP-1 Receptor Agonist Market, By Drug Class, By Route of Administration, By Application, By Distribution Channel, By Geography

PUBLISHED:
PAGES: 170 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4500
PDF & Excel (Multi User License - Up to 7 Users)
USD 7000
PDF & Excel (Corporate User License)
USD 10000

Add to Cart

GLP-1 Receptor Agonist Market is estimated to be valued at USD 31.71 Bn in 2026 and is expected to reach USD 72.33 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.5% from 2026 to 2033.

Report Coverage Report Details
Base Year: 2025 Market Size in 2026: USD 31.71 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2026 To 2033
Forecast Period 2026 to 2033 CAGR: 12.50% 2033 Value Projection: USD 72.33 Bn

GLP 1 receptor agonists are an important class of anti diabetic drugs for the treatment of type 2 diabetes. These mimic the effects of endogenous glucagon like peptide 1 (GLP 1), a peptide hormone released after eating which stimulates insulin secretion and suppresses glucagon secretion in a glucose dependent manner. By binding to and activating the GLP 1 receptor, these drugs induce insulin secretion, inhibit glucagon release, suppress appetite and promote weight loss in diabetic patients. Their superior glucose control efficacy and low risk of hypoglycemia as compared to other classes make them an attractive option, thus, driving the market growth.

Market Dynamics

Global GLP 1 receptor agonist market growth is driven by growing prevalence of diabetes worldwide coupled with the superior therapeutic efficacy of GLP 1 receptor agonists. Rising levels of obesity can increase the risk of type 2 diabetes, thus, boosting demand for more effective medical treatments. However, high development costs and stringent regulatory approvals can hamper the market growth. New product launches featuring improved formulations, flexible dosing options, longer duration of action and multi indication usage can offer growth opportunities. Manufacturers are investing in R&D to expand clinical indications and develop oral versions of these drugs to improve patient convenience.

Key Features of the Study

  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global GLP 1 receptor agonist market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Novo Nordisk A/S, Eli Lilly and Company and Sanofi.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up gradation, market expansion, and marketing tactics.
  • Global GLP 1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global GLP 1 receptor agonist market.

Market Segmentation

  • Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
  • Exenatide
  • Liraglutide
  • Dulaglutide
  • Lixisenatide
  • Albiglutide
  • Semaglutide
  • Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
  • Parenteral
  • Oral
  • Application Insights (Revenue, USD Bn, 2021 - 2033)
  • Type 2 Diabetes Mellitus
  • Obesity
  • Liver Cirrhosis
  • Non-alcoholic Steatohepatitis
  • Others
  • Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
  • Eli Lilly and Company
  • Sanofi
  • Novo Nordisk A/S
  • AstraZeneca
  • Perrigo Company PLC
  • 3M Company
  • Bausch Health
  • Taro Pharmaceutical Industries
  • Novan Inc.
  • Serum Institute of India Pvt. Ltd.
  • Orgenesis biotech company
  • Verrica Pharmaceuticals
  • AbbVie Inc.
  • Lee's Pharmaceutical Holdings Ltd.
  • Cassiopea
  • Glenmark Pharmaceuticals
Product Code: CMI4632

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Drug Class
    • Market Snapshot, By Route of Administration
    • Market Snapshot, By Application
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Acquisitions and Partnerships Scenario
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. GLP-1 Receptor Agonist Market, By Drug Class, 2021 - 2033, (USD Bn)

  • Overview
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Exenatide
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Liraglutide
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Dulaglutide
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Lixisenatide
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Albiglutide
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Semaglutide
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

5. GLP-1 Receptor Agonist Market, By Route of Administration, 2021 - 2033, (USD Bn)

  • Overview
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Parenteral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Oral
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

6. GLP-1 Receptor Agonist Market, By Application, 2021 - 2033, (USD Bn)

  • Overview
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Type 2 Diabetes Mellitus
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Obesity
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Liver Cirrhosis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Non-alcoholic Steatohepatitis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

7. GLP-1 Receptor Agonist Market, By Distribution Channel, 2021 - 2033, (USD Bn)

  • Overview
    • Market Share Analysis, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, 2021 - 2033
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)

8. GLP-1 Receptor Agonist Market, By Region, 2021 - 2033, (USD Bn)

  • Introduction
    • Market Share Analysis, By Region, 2026 and 2033 (%)
    • Y-o-Y Growth Analysis, For Region, 2021 - 2033
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Bn)
      • GCC
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Bn)
      • North Africa
      • Central Africa
      • South Africa

9. Competitive Landscape

  • Company Profiles
    • Eli Lilly and Company
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Sanofi
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novo Nordisk A/S
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AstraZeneca
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Perrigo Company PLC
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • 3M Company
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Bausch Health
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Taro Pharmaceutical Industries
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Novan Inc.
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Serum Institute of India Pvt. Ltd.
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Orgenesis biotech company
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Verrica Pharmaceuticals
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • AbbVie Inc.
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Lee's Pharmaceutical Holdings Ltd
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Cassiopea
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Glenmark Pharmaceuticals
      • Company Highlights
      • Method Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About Us and Sales Contact
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!